Empirical Research Partners
| January 15, 2019
Empirical Research Partners’ U.S. Portfolio Strategist Rochester Cahan and Peter Hafez, Chief Data Scientist at RavenPack, discussed on this study in our 1st Live Chat with the Experts. View an abstract of the webinar below. You can read a summary of this study and request access to the full webcast video and slides.
Recently, Empirical Research Partners showed how news and social media sentiment can improve the timing of stock picking, not only in the US but also internationally. It turns out it is particularly useful in biotech.
This new Empirical Research Partners’ study clearly shows that RavenPack News Sentiment is not only for quantitative investors, but surely also has applications within a fundamental investment framework. The webcast specifically addressed:
Peter Hafez, our Chief Data Scientist, summarized the study below:
According to Empirical Research Partners (ERP), the biotech sector has significantly matured over the years, leaving mega-caps mostly indistinguishable from their pharma parents. Where they do still have a bit of an edge is in their ability to convert research into cash flows. However, they have been confronted with recent growth roadblocks that have significantly reduced their growth rate advantage over traditional pharma, taking them from a double-digit lead in past decades to a more recent +7 percentage point advantage. With patent expiries in the coming years, and considering their existing drug development pipeline, ERP argues that the outlook of biotech looks very similar to pharma.
ERP highlighted another topic driving the convergence between big biotech and pharma: their shared exposure to downward pressure on drug prices. Using RavenPack sentiment data extracted from news stories about product pricing*, Figure 1 illustrates how the relative forward-P/E ratio of biotech to pharma stocks has converged to parity as the optimism surrounding biotech pricing power has waned.
*For example, a positive-sentiment pricing story would be something like “Eli Lilly raises prices for nine drugs, CNBC reports”, while “Pfizer to release new generic Viagra, slashes price by half” would be a negative-sentiment pricing story.
Given the intriguing relationship between drug price sentiment and valuations depicted in Figure 1, ERP took a closer look at whether media sentiment might add value to their modeling efforts in the biopharma space. In particular, they focused on the vitality of the product pipeline, a critical conduit of long-term success or failure in the industry.
Using RavenPack’s database of news events, ERP created a product-pipeline sentiment index for pharma and biotech stocks, see Figure 2. This was done by hand-selecting 36 event types (out of about 3,000 in the whole database) that are related to upcoming drugs. These include stories about patent grants, ongoing clinical trials, FDA priority review grants, and so on. The line in each chart overlays the relative price-to-free cash flow multiple in each industry. Pharma in particular stands out: historically, the valuation of the sector has mostly tracked product-pipeline sentiment, except for the last 18 months where the two have been decoupled. In the report, ERP argued that this could be due to pricing concerns overwhelming everything else, something that would indicate potential optionality on offer, should the glide path of drug prices be less bad than market expectations.
ERP also considered whether particular types of news have long-term implications for stock returns. For example, they highlighted that on average, stocks with positive patent news have outperformed their industry over the following year by more than +6 percentage points, while those with negative patent news have lagged by a point or two, see Figure 3. Similarly, stocks with news confirming that the FDA will grant priority review to a company’s product have outperformed by +7 percentage points in the following year, see Figure 4.
Another useful event highlighted by ERP is the launch of new drugs, see Figure 5. Here, stories about successful new product launches generally carry positive sentiment, and such stocks have outperformed by about +2.5 percentage points per year. Negative sentiment stocks have lagged by a similar amount.
Finally, news around product pricing indicates that, in the long term, being all over the news because of big price increases is a counterproductive strategy as far as equity returns are concerned, see Figure 6.
Putting it all together, Figure 7 summarizes the product- and pricing-related news events that have had the biggest impact on one-year forward returns. Given these results, it is no surprise that the Empirical Research Partners’ Media Sentiment Indicator has been quite effective in both biotech and pharma, see Figure 8.
Please use your business email. If you don't have one, please email us at firstname.lastname@example.org.
We will process your personal data with the purpose of managing your personal account on
RavenPack and offering our services. You can exercise your rights of access, rectification,
erasure, restriction of processing, data portability and objection by emailing us at email@example.com. For more information, you can
Your request has been recorded and a team member will be in touch soon.
We consider incorporating sentiment signals from news, earnings call transcripts, and insider transactions to
boost the risk-adjusted returns, and revive factor performance.
We find stronger, more predictable market reactions when the words of company executives agree with their actions.
We have gathered 12 insights from 2021 research that can be leveraged in 2022.